The FDA has approved RHA Redensity Eye, a hyaluronic acid-based injectable filler, for the treatment of under-eye hollows.

The action extends the existing RHA (resilient hyaluronic acid) filler line into the periocular region with a specific on-label indication for infraorbital hollowing.

What does the approval cover?

RHA fillers use cross-linked hyaluronic acid formulated to retain structural integrity under facial movement. The category includes several formulations differentiated by gel strength, particle size, and intended depth of placement. RHA Redensity, as a member of this line, has been positioned for superficial placement and fine-line correction. The "Eye" suffix signals a dedicated periocular indication distinct from broader facial-volume uses of the family.

The hyaluronic acid matrix binds water in tissue and integrates with native dermal architecture, restoring contour in areas of volume deficit.

What are under-eye hollows?

Under-eye hollows — also called tear-trough deformity, nasojugal groove, or infraorbital hollowing — describe the depression running from the inner canthus along the inferior orbital rim. Contributing factors include age-related descent of the malar fat pad, infraorbital volume loss, congenital anatomy, ligamentous laxity, and post-procedural contour change.

Patients typically present with shadowing in the medial lower lid and an appearance of fatigue that topical camouflage only partially conceals. The concern is largely aesthetic rather than functional.

Why an on-label indication matters

Hyaluronic acid fillers have been injected off-label in the tear-trough region for years. A dedicated indication reshapes practice on several fronts:

• On-label use clarifies documentation, consent, and medicolegal posture
• Manufacturer training and promotion can target the periocular site specifically
• Post-market adverse-event surveillance sharpens for the region
• Reimbursement classification may differ from off-label cosmetic use

What is the periocular risk profile?

The periocular region carries specific filler risks that distinguish it from cheek or temple indications. Vascular occlusion can compromise periorbital tissues. The Tyndall effect — a bluish discoloration visible through thin overlying skin — can result from superficial placement. Contour irregularity and lymphatic congestion are recognized complications when the injector misjudges depth or volume in this thin-skinned area.

These risks have shaped conservative dosing and cannula-based technique in current off-label tear-trough practice.

What does the announcement leave unspecified?

The published report confirms the approval and the indication. It does not detail pivotal-trial endpoints, the formulation's lidocaine content, the syringe volume, the recommended injection depth, or the manufacturer's name. Practitioners evaluating adoption will be watching for the full prescribing information, the trial design, and the longevity data.

Questions practices will want answered

• What injection depth and technique appear in the instructions for use?
• What volume per session does the labeling recommend?
• What longevity data did the pivotal trial report?
• How does the rheology compare with existing RHA fillers?
• What is the acquisition cost, and how does it position against current off-label tear-trough practice?

Forward outlook

The decision gives U.S. aesthetic practices a dedicated on-label filler for one of the most commonly requested injection sites. Whether RHA Redensity Eye becomes the new standard for tear-trough injection or joins the existing toolkit of off-label options will hinge on the full trial data, the published instructions for use, and pricing — details not yet disclosed in the announcement.

Practitioners awaiting the prescribing information and the pivotal trial publication will have the clearest basis for adoption decisions once those documents appear.